213 related articles for article (PubMed ID: 33442247)
1. Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System.
Skubalova Z; Rex S; Sukupova M; Zahalka M; Skladal P; Pribyl J; Michalkova H; Weerasekera A; Adam V; Heger Z
Int J Nanomedicine; 2021; 16():1-14. PubMed ID: 33442247
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
[TBL] [Abstract][Full Text] [Related]
3. Folic acid-mediated re-shuttling of ferritin receptor specificity towards a selective delivery of highly cytotoxic nickel(II) coordination compounds.
Tesarova B; Charousova M; Dostalova S; Bienko A; Kopel P; Kruszyński R; Hynek D; Michalek P; Eckschlager T; Stiborova M; Adam V; Heger Z
Int J Biol Macromol; 2019 Apr; 126():1099-1111. PubMed ID: 30605747
[TBL] [Abstract][Full Text] [Related]
4. Hollow microspheres based on - Folic acid modified - Hydroxypropyl Cellulose and synthetic multi-responsive bio-copolymer for targeted cancer therapy: controlled release of daunorubicin, in vitro and in vivo studies.
Metaxa AF; Efthimiadou EK; Boukos N; Fragogeorgi EA; Loudos G; Kordas G
J Colloid Interface Sci; 2014 Dec; 435():171-81. PubMed ID: 25261841
[TBL] [Abstract][Full Text] [Related]
5. Design, In Silico Modelling, and Functionality Theory of Novel Folate Receptor Targeted Rutin Encapsulated Folic Acid Conjugated Keratin Nanoparticles for Effective Cancer Treatment.
Kunjiappan S; Panneerselvam T; Govindaraj S; Parasuraman P; Baskararaj S; Sankaranarayanan M; Arunachalam S; Babkiewicz E; Jeyakumar A; Lakshmanan M
Anticancer Agents Med Chem; 2019; 19(16):1966-1982. PubMed ID: 31267878
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
Felicetti F; Nervo A; Piovesan A; Berardelli R; Marchisio F; Gallo M; Arvat E
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1093-1098. PubMed ID: 28988510
[TBL] [Abstract][Full Text] [Related]
7. PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
Harmsen S; Meijerman I; Maas-Bakker RF; Beijnen JH; Schellens JH
Eur J Pharm Sci; 2013 Mar; 48(4-5):644-9. PubMed ID: 23277288
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies.
Hagan A; Phillips GJ; Macfarlane WM; Lloyd AW; Czuczman P; Lewis AL
Eur J Pharm Sci; 2017 Apr; 101():22-30. PubMed ID: 28132823
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
[TBL] [Abstract][Full Text] [Related]
10. Folate-functionalized unimolecular micelles based on a degradable amphiphilic dendrimer-like star polymer for cancer cell-targeted drug delivery.
Cao W; Zhou J; Mann A; Wang Y; Zhu L
Biomacromolecules; 2011 Jul; 12(7):2697-707. PubMed ID: 21619062
[TBL] [Abstract][Full Text] [Related]
11. Folic acid-conjugated amphiphilic alternating copolymer as a new active tumor targeting drug delivery platform.
Li X; Szewczuk MR; Malardier-Jugroot C
Drug Des Devel Ther; 2016; 10():4101-4110. PubMed ID: 28008233
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
Azzariti A; Porcelli L; Simone GM; Quatrale AE; Colabufo NA; Berardi F; Perrone R; Zucchetti M; D'Incalci M; Xu JM; Paradiso A
Cancer Chemother Pharmacol; 2010 Jan; 65(2):335-46. PubMed ID: 19495754
[TBL] [Abstract][Full Text] [Related]
13. Four-fold Channel-Nicked Human Ferritin Nanocages for Active Drug Loading and pH-Responsive Drug Release.
Ahn B; Lee SG; Yoon HR; Lee JM; Oh HJ; Kim HM; Jung Y
Angew Chem Int Ed Engl; 2018 Mar; 57(11):2909-2913. PubMed ID: 29359486
[TBL] [Abstract][Full Text] [Related]
14. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy.
Lale SV; R G A; Aravind A; Kumar DS; Koul V
Biomacromolecules; 2014 May; 15(5):1737-52. PubMed ID: 24689987
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
16. The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells.
Zhou Y; Zhang Y; Zou H; Cai N; Chen X; Xu L; Kong X; Liu P
Sci Rep; 2015 Feb; 5():8629. PubMed ID: 25720956
[TBL] [Abstract][Full Text] [Related]
17. Hydrophobicity-enhanced ferritin nanoparticles for efficient encapsulation and targeted delivery of hydrophobic drugs to tumor cells.
Incocciati A; Kubeš J; Piacentini R; Cappelletti C; Botta S; Bertuccini L; Šimůnek T; Boffi A; Macone A; Bonamore A
Protein Sci; 2023 Dec; 32(12):e4819. PubMed ID: 37883077
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
[TBL] [Abstract][Full Text] [Related]
19. Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib.
Jáklová K; Feglarová T; Rex S; Heger Z; Eckschlager T; Hraběta J; Hodek P; Kolárik M; Indra R
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923880
[TBL] [Abstract][Full Text] [Related]
20. Development of Drug Dual-Carriers Delivery System with Mitochondria-Targeted and pH/Heat Responsive Capacity for Synergistic Photothermal-Chemotherapy of Ovarian Cancer.
Guo X; Mei J; Zhang C
Int J Nanomedicine; 2020; 15():301-313. PubMed ID: 32021181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
